Pages that link to "Q39317241"
Jump to navigation
Jump to search
The following pages link to Fibroblast growth factor receptor 2 IIIc as a therapeutic target for colorectal cancer cells (Q39317241):
Displaying 24 items.
- Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes (Q34044691) (← links)
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors (Q34525925) (← links)
- Membrane-Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factor-2 Binding to the Cell Surface and Intracellular Signaling. (Q34799472) (← links)
- Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer (Q34991189) (← links)
- FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. (Q35176181) (← links)
- In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer (Q35870855) (← links)
- The impact of RNA binding motif protein 4-regulated splicing cascade on the progression and metabolism of colorectal cancer cells (Q36545961) (← links)
- Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition (Q36905686) (← links)
- Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer (Q37687476) (← links)
- Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. (Q37697540) (← links)
- Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity (Q37708821) (← links)
- Isoforms of receptors of fibroblast growth factors (Q38204716) (← links)
- Targeting FGF receptors in colorectal cancer: from bench side to bed side (Q38465837) (← links)
- Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer (Q38924208) (← links)
- Aberrant Splicing in Cancer: Mediators of Malignant Progression through an Imperfect Splice Program Shift (Q38994370) (← links)
- Advances and challenges in targeting FGFR signalling in cancer. (Q39183442) (← links)
- Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status (Q40036023) (← links)
- Expression of the FGFR2c mesenchymal splicing variant in human keratinocytes inhibits differentiation and promotes invasion (Q48130149) (← links)
- Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy (Q51048190) (← links)
- Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. (Q52564290) (← links)
- Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases (Q89893291) (← links)
- Emerging roles of histone modifications and HDACs in RNA splicing (Q92513205) (← links)
- Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation (Q92645679) (← links)
- FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential (Q99551276) (← links)